• Home
  • About
  • News
  • Shop
  • Library
  • Events
  • Contact
  • Search
  • Members

Leading the Fight
to treat and cure Tay-Sachs, Canavan and related diseasesdonate button

The DiseasesFind SupportResearchHelp PreventGet Involved


Substrate Inhibition

What is Substrate Inhibition?

Glossary Link Substrate inhibitors are small molecules that pass the blood brain barrier into the Glossary Link central nervous system and decrease the amount of substrate or waste product that accumulates. Think of a clogged sink with the faucet running and turning down the faucet. The water will still fill up the sink but it will take longer.

A visual representation:

a) In most individuals the substrate (water) can be degraded efficiently by adequate Glossary Link enzyme volume (hole in sink).

b) In affected individuals the amount of enzyme is insufficient to efficiently degrade the substrate and it accumulates.

c) In affected individuals treated with substrate synthesis inhibitors the amount of substrate is decreased to match the amount of residual enzyme to prevent accumulation.

What is the Current Status of Substrate Inhibition Research?

Several substrate inhibitors have delayed symptoms and prolonged survival in Tay-Sachs and Sandhoff mouse models but this success has not always successfully translated into the same results with humans.

Zavesca® (miglustat)
Clinical trials in babies, children and adults with Tay-Sachs and Sandhoff of the substrate inhibitor Zavesca® (miglustat) did not show therapeutic benefit. Zavesca is FDA approved for Gaucher which provides families affected by other lysosomal diseases the option of using the drug for off-label use. The FDA did not approve Zavesca®  for Niemann-Pick Type C (NPC) but this use was approved in Europe and Canada.

Zavesca may have a small therapeutic effect on children affected by Juvenile GM-1. Contact our director of family services, Kim Kubilus at This e-mail address is being protected from spambots. You need JavaScript enabled to view it or 800.906.8723 to learn more.

What are the Challenges of Substrate Inhibition?

The primary challenge of substrate inhibition is keeping up with the rapid accumulation of waste production. Zavesca can have significant gastrointestinal side effects such as diarrhea which was extremely debilitating to many participants in the Late Onset Tay-Sachs clinical trial.

Learn more:
http://www.parseghian.org/aboutnpc_drugtrials.html
http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0000259/
http://www.zavesca.com

Research

  • Potential Therapies
    • Overview
    • Gene Therapy
    • Stem Cell
    • Pharmacological Chaperone
    • Substrate Inhibition
    • Enzyme Replacement
    • Bone Marrow Transplant
    • Stop-Codon Read Through Technology
    • Acetate Supplement
    • Biomarkers
    • Natural History Study
    • Evaluating Experimental Therapies
  • Research We Fund
  • Apply for a Grant
  • Clinical Trials
  • Tissue Donation
  • Scientific Meetings

You can make a difference

Make a Gift

Join NTSAD

Sign Up for Email News

Sign up for NTSAD's Topic of the Week or quarterly news.
enter email address


Contact

National Tay-Sachs & Allied Diseases Association
2001 Beacon Street
Suite 204
Boston, MA 02135

info@ntsad.org
800-906-8723 phone
617-277-0134 fax

The Organization

Home
About NTSAD
Mission & Vision
Board of Directors
Staff & Profiles
Chapters & Affiliates
Scientific Advisory Committee
Financials
Our History

News
Library Documents
Glossary
Contact
Search
Member Login


The Diseases

Tay Sachs
Canavan
Sandhoff
GM-1
Other

Leukodystrophies
Lysosomal Storage
Allied Diseases
About Inheritance

Find Support

Annual Family Conference
Become a Member
Free Info Packet
Meet the Families
Register for Research

Infantile & Juvenile
Tay-Sachs, Canavan, Sandhoff, GM-1

Newly Diagnosed
What to Expect
Symptom Management
Special Equipment
Services
Palliative & Hospice Care
Making Memories
Coping
Ways to Help
Grief
Preparing for the Unthinkable

Late Onset
Tay-Sachs, Sandhoff, GM-1

Newly Diagnosed
Communication Skills
Swallowing Difficulties
Employment
Housing
Mental Health
Mobility

Research

Potential Therapies
Overview
Gene Therapy
Stem Cell
Pharmacological Chaperone
Substrate Inhibition
Enzyme Replacement
Bone Marrow Transplant
Stop-Codon Read Through
Acetate Supplement
Biomarkers
Natural History Study
Evaluating Experimental Therapies

Research We Fund
The Research Initiative
NTSAD Research Strategy
Journey to a Cure
Tay-Sachs Gene Therapy Consortium
2011 Grants
2010 Grants
Past Grants
Lysosomal Storage Disease
Research Consortium


Apply for a Grant
Clinical Trials
Scientific Meetings
Donating Tissue

Help Prevent

Carrier Testing
Types of Screening
Jewish Diseases
Tay-Sachs Disease
Prenatal
Screening Centers
Insurance
Education
Family Planning
Genetic Counseling
International Quality Control Program

Get Involved

Donate
Make a Gift
Events
Fundraising Ideas
Day of Hope
Volunteer
Advocate
Raise Awareness
© National Tay-Sachs & Allied Diseases. All rights reserved. Scroll To Top